Komori
EnBio Holdings,Inc (6092) · FactRestated

Adoption of the revenue recognition accounting standard

First written in FY2022-Q1. 3 of 4 entries say "Restated". Latest entry: FY2023.

4entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2022-Q1 – FY20232021: 220212022: 120222023: 12023
Same theme, other companies

91 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 127 companies compared. The sentences above are computed from all 127.
Full recordFilings, disclosures and news, newest first
  1. FY2023RestatedAnnual report

    「The company applied the Implementation Guidance on Accounting Standard for Fair Value Measurement from the beginning of the current consolidated fiscal year. There was no impact on the consolidated financial statements for the current fiscal year.」

    The company applied the implementation guidance for the fair value measurement accounting standard from the beginning of the fiscal year and continued to report that it had no impact on the financial statements.
  2. FY2022-Q3RestatedAnnual report

    「As a result, revenue for the cumulative third quarter increased by ¥195.951 million, while operating profit, ordinary profit and profit before income taxes for the quarter each increased by ¥33.518 million. The opening balance of retained earnings also decreased by ¥45.024 million.」

    The company continued applying the Revenue Recognition Standard. For the cumulative third quarter, revenue increased by ¥195.951 million, operating profit, ordinary profit and other relevant profit measures each increased by ¥33.518 million, and the opening balance of retained earnings decreased by ¥45.024 million.
  3. FY2022-Q2RestatedAnnual report

    「As a result, revenue for the cumulative second quarter increased by ¥101.675 million, while operating profit, ordinary profit and profit before income taxes for the quarter each increased by ¥32.745 million. The opening balance of retained earnings also decreased by ¥45.024 million.」

    The company continued applying the Revenue Recognition Standard, disclosing that its impact on the cumulative second quarter was an increase of ¥101.675 million in revenue and ¥32.745 million each in operating profit, ordinary profit and other relevant profit measures.
  4. FY2022-Q1First statedAnnual report

    「The company applied the Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, 31 March 2020; hereinafter, the “Revenue Recognition Standard”) and other standards from the beginning of the first quarter of the current fiscal year. Revenue is recognised at the amount expected to be received in exchange for the promised goods or services when control of those goods or services is transferred to the customer. As a result, revenue for the cumulative first quarter increased by ¥108.988 million, while operating profit, ordinary profit and profit before income taxes for the quarter each increased by ¥18.616 million. The opening balance of retained earnings also decreased by ¥45.024 million.」

    The company applied the Revenue Recognition Standard and other standards from the beginning of the fiscal year, changing revenue recognition for construction contracts to recognition over a period of time in line with the satisfaction of performance obligations. It disclosed the impact of the application on first-quarter revenue and profit and on retained earnings.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for EnBio Holdings,Inc yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Adoption of the revenue recognition accounting standard | EnBio Holdings,Inc (6092) | Komori